144 related articles for article (PubMed ID: 35390226)
1. PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron.
Acharya A; Pathania AS; Pandey K; Thurman M; Vann KR; Kutateladze TG; Challagundala KB; Durden DL; Byrareddy SN
Clin Transl Med; 2022 Apr; 12(4):e806. PubMed ID: 35390226
[No Abstract] [Full Text] [Related]
2. SRX3177, a CDK4/6-PI3K-BET inhibitor, in combination with an RdRp inhibitor, Molnupiravir, or an entry inhibitor MU-UNMC-2, has potent antiviral activity against the Omicron variant of SARS-CoV-2.
Pandey K; Acharya A; Pal D; Jain P; Singh K; Durden DL; Kutateladze TG; Deshpande AJ; Byrareddy SN
Antiviral Res; 2024 Jul; 227():105904. PubMed ID: 38729306
[TBL] [Abstract][Full Text] [Related]
3. Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication.
Campbell GR; Bruckman RS; Herns SD; Joshi S; Durden DL; Spector SA
J Biol Chem; 2018 Apr; 293(16):5808-5820. PubMed ID: 29475942
[TBL] [Abstract][Full Text] [Related]
4. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Pim kinases triggers a broad antiviral activity by affecting innate immunity and via the PI3K-Akt-mTOR axis the endolysosomal system.
Glitscher M; Benz NI; Sabino C; Murra RO; Hein S; Zahn T; Mhedhbi I; Stefanova D; Bender D; Werner S; Hildt E
Antiviral Res; 2024 Jun; 226():105891. PubMed ID: 38649071
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
7. A commentary on "PI3K-α/mTOR/BRD4 inhibitor alone or in combination with other anti-virals blocks replication of SARS-CoV-2 and its variants of concern including Delta and Omicron".
Muthu S; Venkatesh S
Clin Transl Discov; 2022 Jun; 2(2):e87. PubMed ID: 35942238
[No Abstract] [Full Text] [Related]
8. The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19.
Baranov MV; Bianchi F; van den Bogaart G
Cells; 2020 Dec; 10(1):. PubMed ID: 33375410
[TBL] [Abstract][Full Text] [Related]
9. A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19.
Mashayekhi-Sardoo H; Hosseinjani H
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):17-25. PubMed ID: 34218545
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
Karam BS; Morris RS; Bramante CT; Puskarich M; Zolfaghari EJ; Lotfi-Emran S; Ingraham NE; Charles A; Odde DJ; Tignanelli CJ
J Med Virol; 2021 Apr; 93(4):1843-1846. PubMed ID: 33314219
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
Kayabasi C; Yelken BO; Asik A; Okcanoglu TB; Sogutlu F; Gasimli R; Susluer SY; Saydam G; Avci CB; Gunduz C
Eur J Pharmacol; 2021 Nov; 910():174446. PubMed ID: 34461124
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19.
Basile MS; Cavalli E; McCubrey J; Hernández-Bello J; Muñoz-Valle JF; Fagone P; Nicoletti F
Drug Discov Today; 2022 Mar; 27(3):848-856. PubMed ID: 34763066
[TBL] [Abstract][Full Text] [Related]
13. The Mechanistic Target of Rapamycin (mTOR): Novel Considerations as an Antiviral Treatment.
Maiese K
Curr Neurovasc Res; 2020; 17(3):332-337. PubMed ID: 32334502
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt/mTOR pathway: a potential target for anti-SARS-CoV-2 therapy.
Fattahi S; Khalifehzadeh-Esfahani Z; Mohammad-Rezaei M; Mafi S; Jafarinia M
Immunol Res; 2022 Jun; 70(3):269-275. PubMed ID: 35107743
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus Antivirals.
Fritch EJ; Mordant AL; Gilbert TSK; Wells CI; Yang X; Barker NK; Madden EA; Dinnon KH; Hou YJ; Tse LV; Castillo IN; Sims AC; Moorman NJ; Lakshmanane P; Willson TM; Herring LE; Graves LM; Baric RS
J Proteome Res; 2023 Oct; 22(10):3159-3177. PubMed ID: 37634194
[TBL] [Abstract][Full Text] [Related]
16. Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta.
Fröba M; Große M; Setz C; Rauch P; Auth J; Spanaus L; Münch J; Ruetalo N; Schindler M; Morokutti-Kurz M; Graf P; Prieschl-Grassauer E; Grassauer A; Schubert U
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947999
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain and extraterminal domain inhibitor enhances the antitumor effect of imatinib in gastrointestinal stromal tumours.
Mu J; Sun P; Ma Z; Sun P
J Cell Mol Med; 2020 Feb; 24(4):2519-2530. PubMed ID: 31957165
[TBL] [Abstract][Full Text] [Related]
18. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics.
Liu Q; Kirubakaran S; Hur W; Niepel M; Westover K; Thoreen CC; Wang J; Ni J; Patricelli MP; Vogel K; Riddle S; Waller DL; Traynor R; Sanda T; Zhao Z; Kang SA; Zhao J; Look AT; Sorger PK; Sabatini DM; Gray NS
J Biol Chem; 2012 Mar; 287(13):9742-9752. PubMed ID: 22223645
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Chu J; Xing C; Du Y; Duan T; Liu S; Zhang P; Cheng C; Henley J; Liu X; Qian C; Yin B; Wang HY; Wang RF
Nat Metab; 2021 Nov; 3(11):1466-1475. PubMed ID: 34580494
[TBL] [Abstract][Full Text] [Related]
20. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
